B Guyomarc'h Delasalle

Learn More
OBJECTIVE Proprotein convertase subtilisin kexin/type 9 (PCSK9) is an inhibitor of the low density (LDL) lipoprotein receptor. Plasma PCSK9 is increased by fenofibrate and statins. Here, we determined how standard dose of statin and combined therapy with fenofibrate modulate PCSK9. METHODS Randomized, open-label cross-over study investigating the effect(More)
  • 1